Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-of-illness studies in rare diseases: a scoping review.
García-Pérez L, Linertová R, Valcárcel-Nazco C, Posada M, Gorostiza I, Serrano-Aguilar P. García-Pérez L, et al. Among authors: gorostiza i. Orphanet J Rare Dis. 2021 Apr 13;16(1):178. doi: 10.1186/s13023-021-01815-3. Orphanet J Rare Dis. 2021. PMID: 33849613 Free PMC article. Review.
Cost-of-Illness in Rare Diseases.
Linertová R, García-Pérez L, Gorostiza I. Linertová R, et al. Among authors: gorostiza i. Adv Exp Med Biol. 2017;1031:283-297. doi: 10.1007/978-3-319-67144-4_17. Adv Exp Med Biol. 2017. PMID: 29214579 Review.
Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial.
Gómez-Arango C, Gorostiza I, Úcar E, García-Vivar ML, Pérez CE, De Dios JR, Alvarez B, Ruibal-Escribano A, Stoye C, Vasques M, Belzunegui J, Escobar A, Trancho Z, Ruiz Del Agua A, Del Rio L, Jorquera C, Diez E, Martínez A, Nagore D. Gómez-Arango C, et al. Among authors: gorostiza i. Rheumatol Ther. 2021 Sep;8(3):1323-1339. doi: 10.1007/s40744-021-00345-5. Epub 2021 Jul 18. Rheumatol Ther. 2021. PMID: 34278555 Free PMC article.
Validity of the EQ-5D-5L and reference norms for the Spanish population.
Hernandez G, Garin O, Pardo Y, Vilagut G, Pont À, Suárez M, Neira M, Rajmil L, Gorostiza I, Ramallo-Fariña Y, Cabases J, Alonso J, Ferrer M. Hernandez G, et al. Among authors: gorostiza i. Qual Life Res. 2018 Sep;27(9):2337-2348. doi: 10.1007/s11136-018-1877-5. Epub 2018 May 16. Qual Life Res. 2018. PMID: 29767329
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.
Galíndez-Agirregoikoa E, Prieto-Peña D, Martín-Varillas JL, Joven B, Rusinovich O, Melero-González RB, Ortiz-Sanjuan F, Almodóvar R, Alegre-Sancho JJ, Martínez Á, Sellas-Fernández A, Méndez L, García-Vicuña R, Atienza-Mateo B, Gorostiza I, González-Gay MÁ, Blanco R; Tofacitinib PsA Clinical Practice Collaborative Group. Galíndez-Agirregoikoa E, et al. Among authors: gorostiza i. J Rheumatol. 2021 Oct;48(10):1552-1558. doi: 10.3899/jrheum.201204. Epub 2021 Apr 1. J Rheumatol. 2021. PMID: 33795330
Predictors of mortality of COVID-19 in the general population and nursing homes.
España PP, Bilbao A, García-Gutiérrez S, Lafuente I, Anton-Ladislao A, Villanueva A, Uranga A, Legarreta MJ, Aguirre U, Quintana JM; COVID-19-Osakidetza Working group. España PP, et al. Intern Emerg Med. 2021 Sep;16(6):1487-1496. doi: 10.1007/s11739-020-02594-8. Epub 2021 Jan 5. Intern Emerg Med. 2021. PMID: 33400164 Free PMC article.
18 results